Search

for
Search:

Research

5 / 1000+ results

research Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C.

4 citations , August 2007 in “PubMed”

This report describes a case of alopecia universalis in a woman with hepatitis C linked to pegylated interferon alfa-2b and ribavirin therapy, with hair regrowth observed one year after discontinuation.

research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy

32 citations , October 2004 in “Pharmacotherapy”

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

research Cutaneous necrosis after injection of polyethylene glycol–modified interferon alfa

26 citations , June 2005 in “Journal of The American Academy of Dermatology”

In this study, pegylated interferon alfa-2b injections led to local cutaneous reactions, including cutaneous necrosis, in patients with hepatitis C and chronic myelocytic leukemia, requiring dose modifications or treatment withdrawal in some cases.

research High dose interferon treatment in chronic hepatitis C.

36 citations , January 1993 in “Gut”

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.